According to AngioDynamics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 40.125. At the end of 2022 the company had a P/E ratio of -16.6.
Year | P/E ratio | Change |
---|---|---|
2022 | -16.6 | -40.45% |
2021 | -27.9 | 712.31% |
2020 | -3.43 | -131.92% |
2019 | 10.7 | -73.84% |
2018 | 41.1 | -152.11% |
2017 | -78.8 | 264.5% |
2016 | -21.6 | -69.71% |
2015 | -71.4 | -160.1% |
2014 | 119 | -148.47% |
2013 | -245 | 569.18% |
2012 | -36.6 | -164.31% |
2011 | 57.0 | 85.3% |
2010 | 30.7 | -19.56% |
2009 | 38.2 | 20.03% |
2008 | 31.8 | -168.56% |
2007 | -46.4 | -227.5% |
2006 | 36.4 | -31.52% |
2005 | 53.2 | -3.95% |
2004 | 55.4 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.0 | -72.70% | ๐บ๐ธ USA |
Boston Scientific BSX | 90.9 | 126.58% | ๐บ๐ธ USA |
Teleflex TFX | 25.4 | -36.66% | ๐บ๐ธ USA |
Merit Medical MMSI | 47.3 | 17.82% | ๐บ๐ธ USA |
LeMaitre Vascular LMAT | 63.2 | 57.39% | ๐บ๐ธ USA |
ICU Medical
ICUI | -52.6 | -231.11% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.